

## AMENDMENTS TO THE CLAIMS

Claims 1-9 (canceled).

Claim 10 (currently amended): A substantially pure and isolated peptide having with an amino acid sequence selected from the group consisting of shown in SEQ ID NO. 4, SQD, SLL and SEQ ID NO. 5.

Claims 11-12 (canceled).

Claim 13 (currently amended): A vaccine comprising at least one peptide having an amino acid sequence derived from the encoded by a fragment of a complementary determining region-3 (CDR3) of a T cell receptor gene selected from the group consisting of BV14 and BV16 with a DNA sequence shown in SEQ ID NO: 2 in an individual suffering from rheumatoid arthritis.

Claim 14 (currently amended): The vaccine of claim 13 comprising wherein the amino acid sequence of the at least one peptide having an amino acid sequence selected from the group consisting of is shown in SEQ ID NO. 3, SLS, SEQ ID NO. 4, SQD, SLL and SEQ ID NO. 5.

Claims 15-41 (canceled).

Claim 42 (currently amended): A pharmaceutical composition for suppressing pathogenic T cell response in an individual suffering from rheumatoid arthritis, comprising an immunologically effective amount of a peptide encoded by a DNA with the sequence shown in SEQ ID NO: 2 derived from a single chain T cell receptor variable beta 14 (V.beta.14) or 16 (V.beta.16), or fragments thereof, and a pharmaceutically acceptable carrier.

Claim 43 (canceled):

Claim 44 (currently amended): The pharmaceutical composition of claim 43, wherein the amino acid sequence of the encoded peptide comprises an amino acid sequence selected from the group consisting of is shown in SEQ ID NO. 3, SLS, SEQ ID NO. 4, SQD, SLL and SEQ ID NO. 5.